| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 525.4 | 534.5 | 403.2 |
| Other income | 33.4 | 17.8 | 41.7 |
| Total income | 558.8 | 552.3 | 444.9 |
| Profit before exceptional items & tax | 115.8 | 83.5 | 121.6 |
| Profit before tax | 117.3 | 85.2 | 122.9 |
| Net profit | 85.3 | 65.0 | 93.1 |
| Operating margin | 21.0% | 15.4% | 27.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -8.40% |
|---|---|
| Net profit, quarter on quarter | +31.20% |
| Revenue, year on year | +30.30% |
| Operating profit, year on year | +3.10% |
| Operating profit, quarter on quarter | +25.40% |
BSE results filing, NSE: POLYMED. Figures extracted from the filing.
Poly Medicure Ltd: key numbers
- Share price
- ₹1,724.40
- Market cap
- ₹17,479 Cr
- Revenue (annual)
- ₹1,875 Cr
- Net profit (annual)
- ₹322.1 Cr
- P/E (TTM)
- 55.5×Sector 57.8×
- Promoter holding
- 62.42%+0.00% QoQ
- FII holding
- 5.56%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Poly Medicure Ltd
All →Poly Medicure Annual General Meeting
Poly Medicure conducted its 31st Annual General Meeting on September 5, 2026, via video conferencing. This filing provides a summary of the meeting's proceedings and agenda items.
Poly Medicure Earnings Call Transcript: Key Takeaways
PolyMed Q1FY27 shows strong standalone margin performance beating guidance, but consolidated numbers are dragged by the Middle East crisis and pricing pressure in the renal segment from Chinese dumping.
- Call
- Guides 100% growth
Poly Medicure Investor Presentation: Key Takeaways
Poly Medicure reported strong Q1 FY27 consolidated revenue growth of 30.3% YoY, driven by acquisitions (Citieffe, PendraCare) and domestic expansion. Strategy shifts towards high-complexity medical devices like Cardiology and Orthopaedics.
- Call
- Guides 100% growth
Poly Medicure Earnings Call: Key Takeaways
Poly Medicure reported FY26 consolidated revenue of ₹1,875cr (up 12.3%) and standalone EBITDA of ₹446cr (26.8% margin). The company is transitioning from product-focused to therapy-focused segments like Cardiology and Renal.
Poly Medicure Earnings Call: Key Takeaways
Poly Medicure delivered solid revenue growth despite geopolitical and raw material headwinds, successfully pivoting towards high-margin oncology, renal, and cardiology segments while integrating key acquisitions.
Poly Medicure Earnings Call: Key Takeaways
Poly Medicure (Polymed) reported FY26 consolidated revenue growth of 12.3% YoY. The company is transitioning towards high-end technology segments like Cardiology and Orthopaedics through strategic European acquisitions (Citieffe, PendraCare).